Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript

Bristol-Myers Squibb reported robust Q2 2025 results, with total revenues of $12.3 billion and its growth portfolio expanding 17% year-over-year, driven by key brands including Opdivo, Reblozyl, Breyanzi, and Camzyos. Consequently, the company raised its full-year revenue guidance to $46.5-$47.5 billion and adjusted EPS to $6.35-$6.65, absorbing a $0.57 charge from its strategic BioNTech partnership for a potentially transformative PD-L1 VEGF bispecific. Other significant strategic actions include a radiopharmaceutical deal with Philochem and the divestiture of certain immunology assets to a new entity backed by Bain Capital, while the pipeline anticipates a data-rich period with 7 registration assets, notably milvexian and Cobenfy's Alzheimer's programs, underpinning the firm's long-term growth trajectory and ongoing cost optimization efforts.

Analysis

Bristol-Myers Squibb reported a strong second quarter for 2025, characterized by robust performance in its growth portfolio, which saw sales increase 17% year-over-year. This strength, led by key brands such as Reblozyl ($568 million in sales), Breyanzi (up 122% to $344 million), and Camzyos (up 86% to $260 million), prompted the company to raise its full-year revenue guidance by $700 million to a range of $46.5 billion to $47.5 billion. The better-than-expected performance was further supported by a more moderate decline in the legacy portfolio, with the full-year forecast for Revlimid sales being increased to approximately $3 billion. While the formal non-GAAP EPS guidance was adjusted down to $6.35-$6.65, this was solely due to a $0.57 per share charge for a strategic partnership with BioNTech; underlying operational strength would have otherwise resulted in a guidance increase of approximately $0.20 per share. The quarter was also marked by significant strategic actions aimed at reshaping the company's long-term growth profile, including the BioNTech collaboration for a PD-L1 VEGF bispecific (BNT327), a deal with Philochem to bolster its radiopharmaceutical pipeline, and an innovative out-licensing of five immunology assets to a new entity with Bain Capital. Management emphasized a forthcoming "data-rich period" with 7 registration assets and multiple life cycle management opportunities expected in the next 12-24 months, highlighting upcoming data for milvexian and Cobenfy in Alzheimer's disease as critical catalysts for de-risking its future trajectory.

Key Decisions for Investors

• Investors should look past the headline EPS guidance reduction and recognize the strong underlying operational outperformance, evidenced by the significant $700 million revenue guidance increase and robust demand across the growth portfolio.
• The next 12-24 months are pivotal; closely monitor key pipeline readouts, particularly for Cobenfy in Alzheimer's Disease Psychosis (ADEPT-2 data expected by year-end) and milvexian in 2026, as these events represent significant potential value inflection points.
• Evaluate the company's strategic execution on recent business development, especially the ability to accelerate clinical trials for the BioNTech-partnered asset BNT327, as this is central to the strategy for driving growth in the latter part of the decade.
• While the growth portfolio is performing well, track the commercial adoption trajectory of new launches like Cobenfy, as management's commentary about increasing its field force suggests a concerted effort is needed to accelerate its ramp and meet high long-term expectations.